Frontlight ResearchEarly access
WithdrawnPhase 1/2
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Aug 2023
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Roxadustat in combination with retinoic acid
- Record updated
- 7 July 2026
- Why it stopped
- The study has not actually been conducted.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Low-risk MDS unresponsive to first-line therapy
Who cannot take part
- Severe heart and kidney function bu'quan
- myelofibrosis
About the trial
What the trial wants to find out
Roxadustat has been approved for low-risk MDS clinical trials, but the trial results are not available. For refractory low-risk MDS, the effective rate of roxadustat treatment is about 20-30%, and roxadustat combined with retinoic acid may have better efficacy in the treatment of refractory low-risk MDS.
The group in the trial
- Roxadustat combined with retinoic acid groupTreatment being tested
Treatment: Roxadustat in combination with retinoic acid
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 July 2026